NEW YORK (GenomeWeb News) – The Montreal Heart Institute has partnered with several biotech companies and the Quebec government to launch a C$49.2 million (US$44.6 million) research program to that will use genetic and other biomarkers to develop personalized treatments for cardiovascular diseases.

In the project, dubbed ARTERIA, investigators at MHI's Research Centre and the industry partners will use biomarkers to optimize treatments for CVD that target low-density and high-density lipoproteins, vascular inflammation, and heart rate, MHI said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.